Headlines about Compugen (NASDAQ:CGEN) have trended somewhat negative recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Compugen earned a coverage optimism score of -0.10 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 45.6594187705789 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Separately, Zacks Investment Research raised Compugen from a “sell” rating to a “hold” rating in a research report on Monday, August 28th.

Compugen (CGEN) opened at $2.45 on Friday. Compugen has a twelve month low of $2.25 and a twelve month high of $6.30.

WARNING: This news story was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://www.thecerbatgem.com/2017/12/10/somewhat-critical-media-coverage-somewhat-unlikely-to-affect-compugen-cgen-share-price.html.

About Compugen

Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company’s pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates.

Insider Buying and Selling by Quarter for Compugen (NASDAQ:CGEN)

Receive News & Stock Ratings for Compugen Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen Ltd. and related stocks with our FREE daily email newsletter.